Table 1.
Study data used for the evidence synthesis
| Year | First author | Species | Tumor | Treatment | NT + NC | RMSTT | RMSTC | MR | Data source |
|---|---|---|---|---|---|---|---|---|---|
| 2014 | Han | Humans | GBM | CR+ | 11 + 23 | 41.36 ± 4.02 | 23.70 ± 2.85 | 1.75 ± 0.27 | Figure |
| 2015 | Rieger | Humans | GBM | KD | 8 + 5 | 7.25 ± 1.07 | 5.16 ± 1.29 | 1.41 ± 0.41 | Figure |
| 2018 | Santos | Humans | GBM | KD+ | 17 + 15 | 10.56 ± 0.94 | 8.38 ± 1.49 | 1.26 ± 0.25 | Author |
| 2007 | Zhou | C57BL/6J mice | CT-2A astrocytoma (syn.) | KD | 9 + 7 | 19.78 ± 0.84 | 17.71 ± 0.94 | 1.12 ± 0.08 | Author |
| 2007 | Zhou | C57BL/6J mice | CT-2A astrocytoma (syn.) | CR | 11 + 7 | 31.82 ± 2.26 | 17.71 ± 0.94 | 1.80 ± 0.16 | Author |
| 2007 | Zhou | BALBc/J SCID mice | U87 glioma (xen.) | KD | 7 + 11 | 19.71 ± 0.78 | 21.27 ± 1.84 | 0.93 ± 0.09 | Author |
| 2007 | Zhou | BALBc/J SCID mice | U87 glioma (xen.) | CR | 14 + 11 | 30.36 ± 1.40 | 21.27 ± 1.84 | 1.43 ± 0.14 | Author |
| 2008 | Marsh | C57BL/6J mice | CT-2A astrocytoma (syn.) | CR | 8 + 7 | 30.50 ± 4.09 | 18.86 ± 1.20 | 1.62 ± 0.24 | Figure |
| 2010 | Stafford | C57BL/6J albino mice | GL261 glioma (syn.) | KD | 5 + 5 | 24.00 ± 0.94 | 19.00 ± 0.63 | 1.26 ± 0.06 | Author |
| 2011 | Maurer | Athymic mice | LNT-229 glioma (xen.) | KD | 12 + 12 | 87.83 ± 4.59 | 96.90 ± 3.57 | 0.91 ± 0.06 | Author |
| 2012 | Abdelwahab | C57BL/6J albino mice | GL261 glioma (syn.) | KD | 20 + 19 | 33.90 ± 5.12 | 23.32 ± 1.08 | 1.45 ± 0.23 | Author |
| 2012 | Abdelwahab | C57BL/6J albino mice | GL261 glioma (syn.) | KD+ | 11 + 11 | 97.36 ± 4.93 | 54.73 ± 9.81 | 1.78 ± 0.33 | Figure |
| 2013 | Jiang | Athymic mice | U87 glioma (xen.) | CR | 7 + 7 | 26.71 ± 1.55 | 18.71 ± 0.85 | 1.43 ± 0.11 | Figure |
| 2014 | Rieger | Athymic mice | U87 glioma (xen.) | KD | 8 + 8 | 35.62 ± 0.64 | 33.88 ± 1.53 | 1.05 ± 0.05 | Author |
| 2014 | Rieger | Athymic mice | U87 glioma (xen.) | KD+ | 8 + 8 | 57.50 ± 2.28 | 50.25 ± 2.24 | 1.14 ± 0.07 | Figure |
| 2015 | Martuscello | NOD/SCID mice | L0 glioma (xen.) | KD | 10 + 11 | 48.50 ± 5.63 | 14.55 ± 1.57 | 3.33 ± 0.53 | Figure |
| 2015 | Martuscello | NOD/SCID mice | L2 glioma (xen.) | KD | 5 + 6 | 55.20 ± 8.15 | 25.5 ± 2.38 | 2.17 ± 0.38 | Figure |
| 2016 | De Feyter | Fisher rats | 9 L glioma (xen.) | KD | 10 + 9 | 34.70 ± 1.63 | 33.56 ± 1.33 | 1.07 ± 0.07 | Author |
| 2016 | De Feyter | Fisher rats | RG2 glioma (xen.) | KD | 10 + 11 | 26.30 ± 1.11 | 27.36 ± 0.71 | 0.96 ± 0.05 | Author |
| 2016 | Lussier | C57BL/6J albino mice | GL261 glioma (syn.) | KD | 12 + 11 | 42.17 ± 2.52 | 33.09 ± 1.45 | 1.27 ± 0.09 | Figure |
Subscript “T” denotes treatment group, “C” control group. CR/KD Calorie restriction/ Ketogenic diet as monotherapy, CR+/KD+ Calorie restriction/ ketogenic diet combined with another therapy, syn. syngeneic transplant, xen. xenogeneic transplant